INO - Inovio Pharmaceuticals Inc

INO - Inovio Pharmaceuticals Inc

https://www.inovio.com

Recent News

Powered by Alpha Vantage

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Zacks Commentary • 2 weeks, 4 days ago • score: 0.46

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

Inovio Cuts Q2 Losses by 27%

Motley Fool • 1 month ago • score: 0.32

Inovio Pharmaceuticals ( NASDAQ:INO ) , a biotechnology company developing DNA medicines, released its second-quarter fiscal 2025 earnings on August 12, 2025. The key news from this release is the continued focus on advancing its lead candidate, INO-3107 for recurrent respiratory papillomatosis ( ...

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zacks Commentary • 1 month ago • score: 0.09

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - C3.ai ( NYSE:AI ) , Freeport-McMoRan ( NYSE:FCX )

Benzinga • 2 months ago • score: -0.03

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. WestPark Capital analyst Curtis Shauger initiated coverage on C3.ai, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.

52W High

$7.00

52W Low

$1.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.63

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.09

EV/Revenue (<3 favorable)

610.83

P/S (TTM) (<3 favorable)

813.15

P/B (<3 favorable)

5.20

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.51%

Institutions (25–75% balanced)

19.04%

Shares Outstanding

53,143,000

Float

52,856,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

182,340

Gross Profit (TTM)

-62,049,004

EPS (TTM)

-2.59

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-525.69%

ROE (TTM) (>15% strong)

-1.40%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.14

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—